(2023) revealed that androgen receptor variants in prostate cancer upregulate SLC7A11 and confer ferroptosis resistance, consistent with our identification of SLC7A11 as a central molecule in resistance regulation (70). Here, SLC7A11 is linked to prostate carcinoma.